Time in target range of fasting blood glucose ranges defined by World Health Organization (WHO) and American Diabetes Association (ADA) guidelines and cardiorenal Risk: Insights from two cohorts
Authors' conclusion
The threshold defined by the ADA guidelines serves to protect cardiovascular health across a broader population while not increasing the risk of CKD.
Study context
- Population
- Patients from the Atherosclerosis Risk in Communities and Multi-Ethnic Study of Atherosclerosis studiespooled 2 cohorts
- Participants
- 14,346 patients
- Comparison
- Fasting plasma glucose (FPG) time in target range (TTR) in ADA- vs WHO-defined pre-diabetes ranges
- Outcome
- Major adverse cardiovascular events (MACE)
Methodological detailsARIC and MESA cohorts, Cox regression, TTR calculated by linear interpolation
- ARIC and MESA cohorts
- Cox regression
- TTR calculated by linear interpolation
Pooled result
As reported in the abstract
Hazard ratio (95 % CI)
ADA pre-diabetes rangeadjusted Cox model
1.17(1.09–1.25)
WHO pre-diabetes rangeadjusted Cox model
1.37(1.21–1.57)
100-110 mg/dL
1.24(1.09–1.40)
Further pooled results
- No significant relation between FPG threshold and Chronic kidney disease (CKD)
Original publication
Time in target range of fasting blood glucose ranges defined by WHO and ADA guidelines and cardiorenal Risk: Insights from two cohorts. Diabetes Res Clin Pract. Published 18 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →